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 Introduction 
 Eukaryotic cells change shape and move by assembling ordered 
networks of actin fi laments at their leading edges ( Pollard et al., 
2001 ). The heart of this actin-based motility engine is the actin-
related protein 2/3 (Arp2/3) complex, a seven-subunit protein 
complex that builds cross-linked fi lament arrays by nucleating new 
fi laments from the sides of preexisting fi laments ( Goley and Welch, 
2006 ). Actin-nucleating and cross-linking activities of the Arp2/3 
complex are required to build many cellular structures, including 
lamellipodia and phagocytic cups, and to move endosomes and 
intracellular pathogens through the cytoplasm ( Pollard and Borisy, 
2003 ). The Arp2/3 complex, which is composed of two actin-
related proteins (Arp2 and Arp3) and fi ve accessory proteins, nu-
cleates a new actin fi lament by fi rst binding to the side of a 
preexisting fi lament. Next, the Arp2 and Arp3 subunits form a 
protonucleus that mimics a new fast-growing barbed end of an ac-
tin fi lament ( Robinson et al., 2001 ;  Goley et al., 2004 ;  Nolen et al., 
2004 ). Actin monomers polymerize at this barbed end, elongating 
rapidly toward the plasma membrane, whereas the Arp2/3 complex 
remains bound to the slow-growing pointed end, thereby cross-
linking the new fi lament to the mother fi lament ( Mullins et al., 
1998 ). Arp2 and Arp3 subunits of the complex bind ATP. Although 
ATP hydrolysis is not necessary for actin nucleation, it is thought to 
be necessary for debranching of Arp2/3-branched actin fi laments 
( Martin et al., 2006 ). Wiskott-Aldrich syndrome protein (WASP) 
family proteins are the predominant activators of the Arp2/3 com-
plex. However, in addition to regulation by WASP proteins, recent 
evidence indicates the Arp2/3 complex is phosphorylated by 
serine/threonine kinases. The p21-activated kinase (PAK) phos-
phorylates Thr21 in the ARPC1 subunit ( Vadlamudi et al., 
2004 ), and the MAPK-activated protein kinase 2 phosphorylates 
Ser77 in the ARPC5 subunit ( Singh et al., 2003 ). Although 
phosphorylation of the Arp2/3 complex is suggested to increase 
cell motility, whether phosphorylation directly regulates actin nu-
cleating activity of the Arp2/3 complex has not been reported. 
 Results and discussion 
 Purifi ed Arp2/3 complex is phosphorylated 
 We found that several subunits of the Arp2/3 complex are 
phosphorylated in cells. Using 2D electrophoresis of purified 
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Arp2/3 complex. We now report that the Arp2/3 com-
plex must be phosphorylated on either threonine or tyro-
sine residues to be activated by NPFs. Phosphorylation of 
the Arp2/3 complex is not necessary to bind NPFs or the 
sides of actin fi laments but is critical for binding the pointed 
end of actin fi laments and nucleating actin fi laments. 
Mass spectrometry revealed phosphorylated Thr237 and 
Thr238 in Arp2, which are evolutionarily conserved resi-
dues. In cells, phosphorylation of only the Arp2 subunit 
increases in response to growth factors, and alanine sub-
stitutions of Arp2 T237 and T238 or Y202 inhibits mem-
brane protrusion. These fi ndings reveal an additional level 
of regulation of actin fi lament assembly independent of 
WASP proteins, and show that phosphorylation of the 
Arp2/3 complex provides a logical  “ or gate ” capable 
integrating diverse upstream signals.
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 Arp2/3 complex phosphorylation is 
required for actin nucleation 
 We found that a dephosphorylated Arp2/3 complex does not 
nucleate actin fi laments. Mock-treated (heat-inactivated phos-
phatase) Arp2/3 complex purifi ed from  A. castellani nucleated 
actin fi laments with the C-terminal domain of the nucleation-
promoting factor (NPF) Scar (ScarVCA) faster than with actin 
alone ( Fig. 2 A ), and at rates similar to an untreated complex 
(Fig. S1 A, available at http://www.jcb.org/cgi/content/full/
jcb.200802145/DC1). We calculated the number of barbed 
ends formed by 5 nM of mock-treated Arp2/3 complex, 500 nM 
ScarVCA, and 4  μ M actin to be   3 nM. The number of free 
barbed ends is comparable to similar studies ( Higgs et al., 
1999 ) and in agreement with ScarVCA being a less potent 
Arp2/3 activator compared with N-WASP-VCA ( Zalevsky et al., 
2001 ). The Arp2/3 complex dephosphorylated with AP did not 
nucleate actin filaments with actin alone or in the presence 
of ScarVCA ( Fig. 2 A ) or N-WASP VCA (Fig. S1 B). Arp2/3 
nucleating activity decreased with increasing time of incuba-
tion with the phosphatase (Fig. S1 C). Activity of the Arp2/3 
complex incubated with AP in the presence of phosphatase 
inhibitors was identical to the activity of mock-treated con-
trols (Fig. S1 D). Arp2/3 complex purifi ed from bovine thy-
mus also nucleated actin fi laments but not after treatment with 
AP (Fig. S1 E). 
 We next asked whether tyrosine or serine/threonine phos-
phorylation is necessary for Arp2/3 nucleation activity. Arp2/3 
complex purifi ed from  A. castellani and dephosphorylated with 
YOP or the serine/threonine protein phosphatase 2C  (PP2C  ) 
nucleated actin at rates identical to mock-treated controls ( Fig. 2, 
B and C ). However, when samples were dephosphorylated in se-
ries with YOP and PP2C  , the Arp2/3 complex was unable to 
nucleate actin fi laments ( Fig. 2 D ), which suggests that either ty-
rosine phosphorylation or serine/threonine phosphorylation is 
required. These fi ndings indicate that regulation of actin nucle-
ation by the Arp2/3 complex may act as a logical  “ or gate, ” with 
Arp2/3 complex from  Acanthamoeba castellani , Arp2 and 
Arp3 migrated as multiple spots ( Fig. 1 A ). After dephos-
phorylation with Antarctic phosphatase (AP), a dual-speci-
ficity alkaline phosphatase, Arp2 and Arp3 migrated as 
fewer spots at a more basic pI. These data suggest multiple 
phosphorylated species of Arp2 and at least one of Arp3. 
The presence of multiple spots for both subunits after AP 
treatment suggests posttranslational modifications in addi-
tion to phosphorylation. 
 We also used immunoblotting to determine phosphory-
lation of the Arp2/3 complex purifi ed from  A. castellani . 
Arp2, Arp3, and ARPC1 subunits labeled with antibodies to 
phosphothreonine (pThr) and phosphotyrosine (pTyr;  Fig. 1 B ). 
Labeling of ARPC1 with pThr antibodies is consistent with a 
previous report that this subunit is phosphorylated on Thr21 
( Vadlamudi et al., 2004 ). When the  A. castellani complex was 
dephosphorylated with AP, Arp2 labeling with pThr and pTyr 
antibodies was abolished, ARPC1 labeling with pTyr anti-
bodies was decreased, and Arp3 labeling was unchanged. 
Because AP changed the mobility of Arp3 on 2D gels but not 
Arp3 immunolabeling, we suspect the immunoblot signal 
may be nonspecifi c. Arp3 could be phosphorylated on serine 
residues; however, we were unable to confi rm specifi c label-
ing of any Arp2/3 complex subunit with antiphosphoserine 
antibodies. Tyrosine phosphorylation of Arp2 and ARPC1 
subunits was confirmed by dephosphorylating the Arp2/3 
complex with the tyrosine-specifi c phosphatase from  Yersinia 
entercolitica (YOP;  Fig. 1 B ). Using Arp2/3 complex purifi ed 
from bovine thymus, the Arp2 but not the Arp3 or ARPC1 
subunits labeled with antibodies to pThr and pTyr, and label-
ing was abolished after treatment with AP ( Fig. 1 C ). Immuno-
blotting recombinant human Arp2/3 complex purifi ed from 
insect cells also showed pThr and pTyr labeling of Arp2 be-
fore but not after AP treatment ( Fig. 1 D ). These data suggest 
that phosphorylation of the Arp2/3 complex, particularly Arp2, 
is not species specifi c. 
 Figure 1.  The Arp2/3 complex is threonine- and tyrosine-
phosphorylated in cells. (A) The Arp2/3 complex purifi ed 
from  A. castellani separated by 2D electrophoresis revealed 
that Arp2 migrated as five spots and Arp3 as four spots 
(arrowheads). Pretreatment of the complex with the dual-
specifi city AP resulted in Arp2 migrating as two spots and 
Arp3 migrating as two spots at a more basic pI relative to a 
fi duciary marker (asterisks). (B) The Arp2, Arp3, and ARPC1 
subunits of the Arp2/3 complex purifi ed from  A. castellani 
labeled with antibodies to pThr and pTyr. Dephosphorylation 
of the Arp2/3 complex with AP abolished labeling of Arp2 
with pThr and pTyr antibodies, decreased labeling of ARPC1 
by pTyr antibodies to ARPC1, and did not change labeling of 
Arp3. Dephosphorylation with the tyrosine-specifi c phospha-
tase YOP did not affect labeling of pThr antibodies but abol-
ished labeling of Arp2 with pTyr antibodies and decreased 
labeling of ARPC1. (C) The Arp2 subunit of purifi ed bovine 
Arp2/3 complex labeled with antibodies to both pThr and 
pTyr. (D) The Arp3 and Arp2 subunits of recombinant human 
Arp2/3 complex labeled with antibodies to pThr and pTyr. 
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( K d = 0.88  μ M) and for N-WASP VCA ( K d = 0.34  μ M) was simi-
lar to previous fi ndings ( Pan et al., 2004 ;  Kelly et al., 2006 ) and 
did not change with AP treatment. Additionally, phosphorylation 
did not affect affi nity of the Arp2/3 complex for actin fi laments, 
as determined by cosedimentation with filamentous actin. 
The Arp2/3 complex untreated or dephosphorylated with AP 
(Fig. S2 D), YOP, PP2C  , or YOP and PP2C  (unpublished data) 
bound actin fi laments with a  K d of   1  μ M, which is consistent 
with published data ( Mullins et al., 1998 ). 
 We used pointed-end binding to assay for the ability of the 
complex to undergo the conformational change required for nucle-
ation. Nucleation of a new actin fi lament or binding of Arp2/3 
complex to the pointed end of preformed actin fi laments induces 
nucleotide hydrolysis on the Arp2 subunit ( Dayel and Mullins, 
2004 ). Actin fi laments capped at the barbed end with gelsolin 
(100 nM gelsolin-actin seeds) elongated from the pointed end in 
the absence of Arp2/3 complex and excess actin monomer ( Fig. 2 E ). 
The addition of mock-treated Arp2/3 complex, a pointed end – 
capping protein ( Mullins et al., 1998 ), slowed pointed-end elongation. 
either tyrosine or serine/threonine phosphorylation being neces-
sary for activation. 
 Phosphorylation of the Arp2/3 complex 
is necessary to cap the pointed ends of 
actin fi laments 
 Phosphorylation could control nucleation activity by regulating 
several properties, including the association of subunits, the affi n-
ity of the Arp2/3 complex for NPFs, the affi nity of the complex 
for the sides of actin fi laments, and/or the ability of the complex 
to undergo the conformational change required for nucleation. 
Affi nity purifi cation using N-WASP VCA bound to agarose beads 
indicated an intact complex with and without AP treatment 
(Fig. S2 A, available at http://www.jcb.org/cgi/content/full/
jcb.200802145/DC1). These data also indicated that AP-treated 
Arp2/3 complex binds to NPFs and we found that phosphory-
lation did not affect the affi nity of the Arp2/3 complex for binding 
ScarVCA (Fig. S2 B) or N-WASP VCA (Fig. S2 C). The affi nity 
of untreated and mock-treated Arp2/3 complex for ScarVCA 
 Figure 2.  The Arp2/3 complex must be 
phosphorylated to nucleate actin fi laments. 
(A) Polymerization assays show that Arp2/3 
complex in the absence (red) and presence of 
500 nM ScarVCA (blue) nucleates actin faster 
than actin alone (black). Arp2/3 complex 
dephosphorylated with the dual-specifi city 
phosphatase AP (AP-Arp2/3) did not nucleate 
actin fi laments in the absence (green) or pres-
ence of ScarVCA (orange). (B and C) Arp2/3 
complex dephosphorylated with the tyrosine-
specifi c phosphatase YOP (YOP-Arp2/3; B) 
or the serine/threonine phosphatase PP2C  
(PP2C  -Arp2/3; C) nucleated actin fi laments 
at rates similar to control Arp2/3 complex in 
the absence (green) or presence of ScarVCA 
(orange). (D) Arp2/3 complex dephosphory-
lated in series with YOP and PP2C  (PP2C  /
YOP-Arp2/3) did not nucleate actin fi laments 
either alone (green) or with ScarVCA (orange). 
(E) Phosphorylation of the Arp2/3 complex is 
necessary to cap the pointed ends of actin fi l-
aments. 100 nM actin fi laments capped at the 
barbed end with gelsolin were capped at the 
pointed end by mock-treated Arp2/3 complex 
(blue circles) but not by AP-dephosphorylated 
Arp2/3 complex (red triangles). (F) Gelsolin-
capped actin fi laments were titrated with 
mock-treated Arp2/3 complex (blue) or AP-
dephosphorylated Arp2/3 complex. 
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We identifi ed two threonine phosphorylation sites on the Arp2 
subunit, T237 and T238 (Fig. S3 A, available at http://www.jcb
.org/cgi/content/full/jcb.200802145/DC1), but did not detect pThr 
residues in Arp3 or pSer residues in Arp2 or Arp3. We also did 
not detect pTyr residues on Arp2 or Arp3, despite immunoblotting 
data indicating that Arp2 labels with anti-pTyr antibodies before 
but not after treatment with AP or YOP. Because the amino acid 
sequence of  A. castellani ARPC1 is not known, we were unable 
to identify phosphorylated sites by mass spectrometry. 
 Based on the atomic structure of the Arp2/3 complex deter-
mined by  Robinson et al. (2001) , T237 and T238 of the Arp2 sub-
unit are in subdomain IV near the interface of the Arp3, ARPC2, 
and ARPC4 subunits ( Fig. 3 A ). The side chains of Arp2 T237 and 
T238 are directly adjacent to the basic side chains of R105 and 
R106, respectively, in the ARPC4 subunit ( Fig. 3 A ). Phos-
phorylated T237 and T238 of the Arp2 complex could form salt 
Mock-treated Arp2/3 complex bound pointed ends with an appar-
ent  K d of   42 nM, which is similar to previously described values 
( Mullins et al., 1998 ). The Arp2/3 complex dephosphorylated with 
AP did not block elongation of barbed end – capped actin fi laments. 
The rate of pointed-end elongation decreased when titrated with 
untreated Arp2/3 complex but remained nearly constant when 
titrated with AP-dephosphorylated Arp2/3 complex ( Fig. 2 F ). 
Because capping of the actin fi lament pointed end is similar to the 
nucleation step, these data indicate that the complex must be phos-
phorylated to undergo the conformation change required for 
actin nucleation. 
 Phosphorylation of the Arp2 subunit is on 
conserved residues and is regulated in cells 
 We used nanoelectrospray LC-MS/MS to identify phosphory-
lated residues in Arp2/3 complex purifi ed from  A. castellani cells. 
 Figure 3.  The putative phosphorylation sites are conserved. (A) Phosphorylated T237, T238, and Y202 of Arp2 were mapped to the Arp2/3 complex 
crystal structure obtained by  Robinson et al. (2001) . From the crystal structure, T237 and T238 of Arp2 are adjacent to R105 and R106 of ARPC4, and 
Y202 of Arp2 is adjacent to R409 of Arp3. (inset) Enlarged view of the boxed region. (B) The proposed phosphorylation sites on the Arp2 subunit and 
adjacent arginine residues in ARPC4 and Arp3 are conserved in nine organisms. 
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1.21-fold at 180s, as determined by immunoprecipitating Arp2/3 
complex from unlabeled cells and immunoblotting with anti-
bodies to pThr and pTyr ( Fig. 4 C ). 
 Phosphorylation of Arp2 is necessary for 
lamellipodia formation 
 We asked whether the identifi ed pThr residues and the speculated 
pTyr residue in Arp2 were functionally signifi cant by analyzing 
lamellipodia formation by  Drosophila melanogaster Schneider 
S2 cells. When plated on coverslips coated with concanavalin A, 
S2 cells extended a circular, fl at lamellipodia ( Fig. 5 A ), which is 
similar to previous fi ndings ( Rogers et al., 2003 ). When the 
Arp2/3 complex is inactivated by depletion of the ARPC3 or 
ARPC4 subunits by RNAi, S2 cells exhibit a stellate morphology 
with formations that extend radially around the cell body ( Rogers 
et al., 2002 ;  Iwasa and Mullins, 2007 ). We observed a similar 
stellate phenotype when S2 cells were depleted of the Arp2 sub-
unit by Arp2 siRNA ( Fig. 5 A ). Transient expression of wild-type 
Arp2 fused to GFP (Arp2-WT-GFP) in Arp2-depleted cells re-
stored a wild-type phenotype with fl at circular lamellipodia ( Fig. 5, 
A and B ). Expression of Arp2 containing alanine substitutions for 
T237 and T238 (Arp2-T237/238A-GFP) or for Y202 (Arp2-
Y202A-GFP) also restored lamellipodia formation ( Fig. 5, A 
and B ). In contrast, expression of Arp2-T237/238A-Y202A-GFP 
did not restore lamellipodia formation, and cells retained a stellate 
phenotype. These fi ndings are consistent with our in vitro actin 
polymerization data suggesting that either threonine or tyrosine 
phosphorylation of the complex is necessary for nucleating activity. 
bridges with R105 and R106 of ARPC4 to perhaps stabilize the 
Arp2/3 complex in an active conformation. Molecular dynamics 
simulations suggest that Arp2 pT237 interacts exclusively with 
R105 of ARPC4 (unpublished data). Because Arp2 pTyr residues 
were suggested by immunoblotting but were not identifi ed by 
mass spectrometry, we searched the Arp2 structure for potential 
tyrosine phosphorylation sites that might interact with basic resi-
dues of adjacent subunits. Of particular interest was Y202 in sub-
domain IV, which is adjacent to R409 in the Arp3 subunit. 
Sequence alignments of Arp2/3 subunits of nine organisms re-
vealed that Arp2 T237, T238, and Y202; Arp3 R409; and ARPC4 
R105 and R106 are evolutionary conserved from yeasts and slime 
molds to mammals ( Fig. 3 B ). 
 To determine whether phosphorylation of Arp2/3 complex 
subunits is regulated in cells, MTLn3 epithelial carcinoma 
cells were metabolically labeled with [ 32 P]orthophosphate and 
stimulated with 10 nM EGF, and the Arp2/3 complex was 
immunoprecipitated with antibodies to the ARPC1 subunit. 
Phosphorylation of only the Arp2 subunit was detected in un-
stimulated and EGF-treated cells ( Fig. 4 A ). Phosphorylation of 
other unidentifi ed proteins was detected in the immune com-
plex; however, none of these proteins migrated with Arp2/3 
complex subunits. EGF induced a time-dependent but transient 
increase in Arp2 phosphorylation ( Fig. 4, A and B ). Phosphory-
lation rapidly increased at 90 s, was maximal at 180 s, with a 
twofold increase, and was not signifi cantly different compared 
with quiescence at 360 s. In response to EGF, labeling by anti-
pThr increased 1.3-fold and labeling by anti-pTyr increased 
 Figure 4.  Phosphorylation of the Arp2 is 
regulated in cells. (A) Immunoprecipitation of 
the Arp2/3 complex with antibodies to ARPC1 
from MTLn3 epithelial cells metabolically la-
beled with [ 32 P]orthophosphate indicated that 
the Arp2 subunit is phosphorylated in unstimu-
lated cells, and phosphorylation increased after 
stimulation with EGF. (B) Quantifi cation of time-
dependent Arp2 phosphorylation. Data are ex-
pressed as the fold increase of phosphorylation 
in the absence of EGF and represent means  ± 
SD of fi ve separate cell preparations. (C) The 
Arp2/3 complex was immunoprecipitated 
from quiescent and EGF-stimulated MTLn3 
cells. Labeling of Arp2 with antibodies to pThr 
and pTyr increased   1.3- and 1.21-fold after 
EGF stimulation, respectively. 
JCB • VOLUME 182 • NUMBER 4 • 2008 652
We also confi rmed that recombinant wild-type but not mutant 
Arp2 in S2 cells was phosphorylated on threonine and tyrosine 
residues (Fig. S3, B and C). Complexes immunoprecipitated with 
antibodies to GFP and immunoblotted with antibodies to pThr 
and pTyr showed labeling of Arp2-WT but not Arp2-T237/238-
Y202A, which suggests that Y202 is necessary for tyrosine 
phosphorylation of Arp2 in cells. Whether this refl ects a direct 
requirement for Y202 phosphorylation or a necessary role of 
Y202 for phosphorylation of a different Tyr residue in Arp2 re-
mains to be determined. 
 Our data show that the Arp2/3 complex must be phosphor-
ylated on threonine or tyrosine residues for actin-nucleating 
activity. Phosphorylation is necessary but not suffi cient for nu-
cleating activity of the complex, which must be stimulated by 
NPFs. However, NPFs are not suffi cient in the absence of Arp2/3 
complex phosphorylation. In cells, lamellipodia formation is 
inhibited by alanine substitutions in Arp2 T237/238-Y202. 
Whether phosphorylation of these residues is necessary for nu-
cleating activity of the complex or whether they might function 
as docking sites for a kinase remains to be determined. How-
ever, based on their potential charge interactions with other sub-
units of the complex, we predict that phosphorylation of Arp2 
T237/238 or Y202 stabilizes the Arp2/3 complex in an active 
conformation ( Fig. 5 C ). Although current models of Arp2/3 
complex regulation do not incorporate a role for phosphory-
lation of subunits ( Goley and Welch, 2006 ;  Stradal and Scita, 
2006 ), a requirement for either threonine or tyrosine phosphory-
lation is an effective mechanism for integrating diverse upstream 
signals regulating actin fi lament assembly. 
 Materials and methods 
 Protein purifi cation 
 Arp2/3 complex and actin from  A. castellani were purifi ed as described 
previously ( Zalevsky et al., 2001 ). Bovine Arp2/3 complex was a gift from 
T. Pollard (Yale University, New Haven, CT), and recombinant human 
Arp2/3 complex was a gift from M. Welch (University of California, Berke-
ley, Berkeley, CA). N-WASP VCA and ScarVCA were expressed in  E. coli 
and purifi ed as described previously ( Zalevsky et al., 2001 ). 
 2D electrophoresis 
 The Arp2/3 complex was precipitated by chloroform/methanol extraction 
and resuspended in fi rst-dimension rehydration buffer (8 M urea, 2% CHAPS, 
0.5% pharmalyte, pH 3 – 10, 0.002% bromophenol blue, and 18 mM DTT). 
Protein samples were separated in the fi rst dimension with an Ettan IGphor 3 
IEF system (GE Healthcare) on Immobiline Dry Strips (pH 3 – 10NL, 7 cm; 
GE Healthcare) at 1,500 volt hours for 10 h. The focused proteins were 
then separated in the second dimension on Nu-PAGE 12% Bis-Tris precast 
gels (Invitrogen). 
 SDS-PAGE and immunoblotting 
 Arp2/3 complex was separated on 12.5% SDS-PAGE gels and transferred 
to Immobilon-P (Millipore) by standard methods. Immunoblots were incu-
bated in 3% BSA in TBS-T (25 mM Tris, pH 7.5, 150 mM NaCl, and 0.1% 
Tween-20) for 2 h, and monoclonal anti-pTyr (Cell Signaling Technology) 
or polyclonal anti-pThr (Invitrogen) were added at 200 ng/ml. Primary anti-
bodies were detected with horseradish peroxidase – conjugated anti – mouse 
and anti – rabbit antibodies (BioRad Laboratories), respectively, and visual-
ized with an ECL chemiluminescence kit (Pierce). 
 Arp2/3 complex dephosphorylation 
 Arp2/3 complex was dephosphorylated with AP (New England Biolabs, 
Inc.). Arp2/3 complex was diluted 1:1 with 2 mM Tris, pH 8, and combined 
with HipH Buffer (50 mM Tris, pH 8, 1 mM Mg 2 Cl 2 , and 0.1 mM ZnCl 2 ) 
containing 1 U AP and incubated at 30 ° C for 1.5 h. For mock-treated 
 Figure 5.  Phosphorylation of Arp2 is necessary for lamellipodia formation. 
(A) Control, luciferase RNAi-treated  D. melanogaster S2 cells on con-
canavalin A – coated coverslips spread symmetrical, round lamellipodia. 
S2 cells depleted of the Arp2 subunit by siRNA (Arp2 RNAi) exhibited a 
stellate morphology with membrane protrusions radiating from the cell body. 
A wild-type morphology of circular lamellipodia was restored in Arp2-
depleted S2 cells expressing wild-type Arp2-GFP (Arp2-WT-GFP), or mu-
tated Arp2-T237/238A-GFP or Arp2-Y202A-GFP. Arp2-depleted S2 cells 
expressing the triple mutant Arp2-T237/238A-Y202A-GFP remained stel-
late. Bar, 5  μ M. (B) The number of cells with wild-type or stellate morphol-
ogy were scored for the indicated conditions and expressed as the mean  ± 
SD of three separate cell preparations, with  > 500 cells scored for each 
condition per cell preparation. (C) Model for activation of the Arp2/3 
complex by phosphorylation of the Arp2 subunit. In the  “ inactive ” form of 
the Arp2/3 complex, the Arp2 and Arp3 subunits are splayed open. Phos-
phorylated T237/T238 and Y202 residues in Arp2 interact with arginine 
residues on adjacent subunits to maintain a conformation that stabilizes the 
complex in the  “ active ” form. This conformation aligns the Arp2 and Arp3 
subunits to form a protonucleus for actin nucleation. 
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RNA was amplifi ed using a T7 Megascript RNA amplifi cation kit (Ambion). 
Plasmids expressing  D. melanogaster Arp2 were constructed using Gate-
way cloning technology (Invitrogen).  D. melanogaster  Arp2 was cloned 
from an S2 cDNA library, sequenced, and inserted into a pENTR-D-TOPO 
plasmid (Invitrogen). Arp2 was then cloned into an expression vector con-
taining a single C-terminal GFP. Mutant Arp2 sequences were constructed 
using a QuikChange Mutagenesis kit (Stratagene). RNAi was performed 
over 7 d as described by  Rogers et al. (2003) . In brief, 5  μ g Arp2 double-
stranded RNA was added to 24-well plates containing 3  × 10 5 cells on day 
one and again on day three. Cells were transformed with plasmids using 
Cellfectin LTX (Invitrogen) on day fi ve. Plasmid transfection in S2 cells 
was   30% effi cient. On day seven, S2 cells were prepared for microscopy 
as described previously ( Rogers et al., 2003 ) and mounted in fl uorescent 
mounting medium (Dako). Images were acquired with a Roper SPOT 
charge-coupled device camera (Roper Scientifi c) on an Axiophot microscope 
(Carl Zeiss, Inc.) at 40 × magnifi cation at room temperature with Roper 
SPOT acquisition software. Images were assembled into fi gures using Photo-
shop (Adobe). 
 Arp2/3 structural model 
 Arp2/3 complex structure was analyzed using PyMol molecular viewing 
software and PDB 1K8K ( Robinson et al., 2001 ). Images were imported 
and notated using Illustrator software (Adobe). 
 Online supplemental material 
 Fig. S1 shows data related to AP treatment of Arp2/3 complex with 
mock-treated samples, N-WASP VCA, and phosphatase inhibitors. Fig. S2 
shows the effect of AP treatment on Arp2/3 complex subunit association, 
NPF-binding, and F-actin binding. Fig. S3 shows mass spectrometry data 
for phospho-Arp2 and immunoblots of Arp2-GFP from S2 cells. Online sup-
plemental material is available at http://www.jcb.org/cgi/content/full/
jcb.200802145/DC1. 
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